Institutional investors hold a majority ownership of EXAS through the 68.19% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended December 2012, these large investors purchased a net $2.0 million shares.
| Individual stakeholders | 6.94% |
| Other institutional | 36.01% |
| Mutual fund holders | 32.18% |